中恒集团：控股子公司莱美药业产品尼可地尔片拟中选第十一批全国药品集中采购

Core Viewpoint - Zhongheng Group's subsidiary, Laimei Pharmaceutical, is participating in the 11th batch of national centralized drug procurement and aims to be selected for the procurement of Nicorandil tablets, which have not yet commenced sales [1] Group 1 - The potential selection for procurement could enhance product sales and market expansion for the company [1] - Successful procurement and contract signing would positively impact the company's brand influence and long-term development [1] - There are uncertainties regarding the bidding results and contract signing, and various factors affect drug production and sales [1]